This is an aggregated industry headline. Read the full story at BioPharma Dive →
3 takeaways from a European obesity scientific meeting
Eli Lilly impressed with its amylin-Zepbound combination data. Elsewhere, Novo demonstrated continued weight loss following a switch to oral and AbbVie and Boehringer gave glimpses into their contenders.
By BioPharma Dive
· Oct 1, 2026
· via BioPharma Dive
RxInsider combines reported facts with industry analysis and informed inference. Forward-looking reads, market commentary, and interpretive framing reflect analysis of available reporting and known facts, not confirmed outcomes.
Tags
theweekformat:headlineheadlineBioPharma Dive
The Insider - Weekly pharma intelligence
Deals, negotiations, and policy analysis. Delivered when it matters.
No sponsored content. No noise. Unsubscribe anytime.
More from The Week
All The Week →
The WeekBriefing
AJMC reported that Medicare drug price negotiations are yielding uneven out-of-pocket savings. The policy sign…
The WeekPharmaceutical Technology ↗
China's NMPA has approved the MAA for Foresee Pharmaceuticals' Camcevi 42 mg to treat adult patients with adva…
The WeekKFF Health News ↗
Health care's AI future is being built right now. The open question is "for whom?" Dr. Uché Blackstock - emerg…